We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

41 hedge funds and large institutions have $144M invested in Protagonist Therapeutics in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 17 increasing their positions, 9 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

89% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 9

56% more capital invested

Capital invested by funds: $91.8M → $144M (+$51.8M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.08% less ownership

Funds ownership: 48.16% → 48.08% (-0.08%)

5% less funds holding

Funds holding: 43 → 41 (-2)

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

Holders
41
Holders Change
-2
Holders Change %
-4.65%
% of All Funds
1.02%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
5
Increased
17
Reduced
9
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
PC
Polar Capital
United Kingdom
+$692K
2
BCM
Bridgeway Capital Management
Texas
+$540K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$422K
4
FSA
Franklin Street Advisors
North Carolina
+$231K
5
First Manhattan
First Manhattan
New York
+$230K

Top Sellers

1
Millennium Management
Millennium Management
New York
-$891K
2
SAM
Senzar Asset Management
New York
-$727K
3
GAMA
Graticule Asia Macro Advisors
New York
-$328K
4
Deutsche Bank
Deutsche Bank
Germany
-$320K
5
Renaissance Technologies
Renaissance Technologies
New York
-$294K
Name Holding Trade Value Shares
Change 		Change in
Stake
Manulife (Manufacturers Life Insurance)
26
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$158K +$108K +7,772 +698%
Deutsche Bank
27
Deutsche Bank
Germany
$152K -$320K -23,096 -73%
TCM
28
Tekla Capital Management
Massachusetts
$138K +$108K +7,822 New
New York State Common Retirement Fund
29
New York State Common Retirement Fund
New York
$134K – – –
AIG
30
American International Group
New York
$111K +$6.51K +470 +8%
NFA
31
Nationwide Fund Advisors
Ohio
$77K – – –
SO
32
STRS Ohio
Ohio
$42K – – –
TRCT
33
Tower Research Capital (TRC)
New York
$31K +$24.2K +1,750 New
Legal & General Group
34
Legal & General Group
United Kingdom
$30K +$9.57K +691 +67%
Royal Bank of Canada
35
Royal Bank of Canada
Ontario, Canada
$13K +$9.78K +706 +1,358%
BNP Paribas Financial Markets
36
BNP Paribas Financial Markets
France
$11.6K -$900 -65 -9%
Bank of America
37
Bank of America
North Carolina
$11K +$8.36K +604 +30,200%
Bank of Montreal
38
Bank of Montreal
Ontario, Canada
$9K -$332 -24 -5%
AIP
39
Ameritas Investment Partners
Nebraska
$8K – – –
UBS Group
40
UBS Group
Switzerland
$5K -$18.9K -1,362 -82%
Barclays
41
Barclays
United Kingdom
$4K -$3.43K -248 -53%
GAMA
42
Graticule Asia Macro Advisors
New York
– -$328K -29,027 Closed
Renaissance Technologies
43
Renaissance Technologies
New York
– -$294K -25,989 Closed
NCMW
44
Northern Capital Management (Wisconsin)
Wisconsin
– -$188K -16,665 Closed
JP Morgan Chase
45
JP Morgan Chase
New York
– -$96K -8,468 Closed
Creative Planning
46
Creative Planning
Kansas
– -$2K -177 Closed
MAM
47
Meeder Asset Management
Ohio
– -$1K -79 Closed
Citigroup
48
Citigroup
New York
– -$1K -63 Closed
1
2

PTGX Hedge Fund Activity: Q3 2017 in Review

41 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q3 2017, worth a combined $144M — up 56% from $91.8M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of PTGX and 5 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 17 added.

The largest buyer was Polar Capital, adding an estimated $692K. The largest seller was Millennium Management, cutting an estimated $891K.

  • 41 institutional investors held Protagonist Therapeutics (PTGX) as of Q3 2017, down from 43 in Q2 2017.
  • Funds reported $144M of Protagonist Therapeutics stock for Q3 2017, up 56% quarter-over-quarter.
  • 5 funds opened new Protagonist Therapeutics positions in Q3 2017 and 7 closed out, a net change of -2 holders.
  • The largest Protagonist Therapeutics buyer in Q3 2017 was Polar Capital, an estimated $692K added.
  • The largest Protagonist Therapeutics seller in Q3 2017 was Millennium Management, an estimated $891K sold.

Based on aggregated 13F filings for Q3 2017.